

Oral Medications That Should Not Be Crushed or Altered

The following table contains available drugs that have characteristics that may make it inappropriate to crush or alter the dosage form to help facilitate drug delivery. There are a variety of reasons for crushing tablets or capsule contents prior to administering to the patient. Patients may have enteral feeding which do not permit the administration of tablets or capsules, an oral solution for a particular medication may not be available from the manufacturer or readily prepared by pharmacy, patients may have difficulty swallowing capsules or tablets, or mixing of powdered medication with food or drink may make the drug more palatable. **Generally, medications which should not be crushed fall into one of the following categories:**

Extended Release Products: The formulation of some tablets is specialized as to allow the medication within it to be slowly released into the body. This may be accomplished by centering the drug within the core of the tablet, with a subsequent shedding of multiple layers around the core. Wax melts in the GI tract, releasing drug contained within the wax matrix (e.g., OxyCONTIN). Capsules may contain beads which have multiple layers which are slowly dissolved with time.

Medications Which Are Irritating to the Stomach: Tablets which are irritating to the stomach may be enteric-coated which delays release of the drug until the time when it reaches the small intestine. Enteric-coated aspirin is an example of this.

Foul-Tasting Medication: Some drugs are quite unpleasant to taste so the manufacturer coats the tablet in a sugar coating to increase its palatability. By crushing the tablet, this sugar coating is lost and the patient tastes the unpleasant tasting medication.

Sublingual Medication: Medication intended for use under the tongue should not be crushed. While it appears to be obvious, it is not always easy to determine if a medication is to be used sublingually. Sublingual medications should indicate on the package that they are intended for sublingual use.

Effervescent Tablets: These are tablets which, when dropped into a liquid, quickly dissolve to yield a solution. Many effervescent tablets, when crushed, lose their ability to quickly dissolve.

Potentially Hazardous Substances: Certain drugs, including antineoplastic agents, hormonal agents, some antivirals, some bioengineered agents, and other miscellaneous drugs, are considered potentially hazardous when used in humans based on their characteristics. Examples of these characteristics include carcinogenicity, teratogenicity, reproductive toxicity, organ toxicity at low doses, genotoxicity, or new drugs with structural and toxicity profiles similar to existing hazardous drugs. Exposure to these substances can result in adverse effects and should be avoided. Crushing or breaking a tablet or opening a capsule of a potentially hazardous substance may increase the risk of exposure to the substance through skin contact, inhalation, or accidental ingestion. The extent of exposure, potency, and toxicity of the hazardous substance determines the health risk. Institutions have policies and procedures to follow when handling any potentially hazardous substance. **Note: All potentially hazardous substances may not be represented in this table. Refer to institution-specific guidelines for precautions to observe when handling hazardous substances.**

Common Abbreviations for Extended Release Products

| | |
|-----|---------------------------|
| CD | Controlled dose |
| CR | Controlled release |
| CRT | Controlled release tablet |
| LA | Long-acting |
| SR | Sustained release |
| TR | Timed release |
| TD | Time delay |
| SA | Sustained action |
| XL | Extended release |
| XR | Extended release |

Recommendations

1. It is not advisable to crush certain medications.
2. Consult individual monographs prior to crushing capsule or tablet.
3. If crushing a tablet or capsule is contraindicated, consult with your pharmacist to determine whether an oral solution exists or can be compounded.

| Drug Product | Dosage Form | Reasons/Comments |
|---|------------------------------|---|
| Abilify MyCite Kits (ARIPiprazole) | Tablet | Drug-device combination |
| Absorica, Absorica LD (ISotretinoin) | Capsule | Mucous membrane irritant; teratogenic potential |
| Acetaminophen ER | Tablet | Extended release |
| Aciphex (RABEprazole) | Tablet | Extended release |
| Aciphex Sprinkle (RABEprazole) | Capsule | Slow release. Capsule may be opened and contents sprinkled on soft food (e.g., applesauce, fruit- or vegetable-based baby food, yogurt) or emptied into a small amount of liquid (e.g., infant formula, apple juice, pediatric electrolyte solution). Granules should not be chewed or crushed. |
| Acticlate (Doxycycline Hyclate) | Capsule, tablet | Film-coated. Tablet is scored and may be split; 150 mg tablets can be broken into two-thirds or one-third to provide a 100 mg and 50 mg strength, respectively. |
| Actiq (FentaNYL) | Lozenge | Slow release. This lollipop delivery system requires the patient to dissolve it slowly. |
| Actoplus Met XR (Pioglitazone and Metformin) | Tablet | Variable release |
| Actonel (Risedronate) | Tablet | Irritant. Chewed, crushed, or sucked tablets may cause oropharyngeal irritation. |
| Adalat CC (NIFEdipine) | Tablet | Extended release |
| Adderall XR (Dextroamphetamine and Amphetamine) | Capsule | Extended release _a |
| Adenovirus (Types 4, 7) Vaccine | Tablet | Teratogenic potential; enteric-coated; do not disrupt tablet to avoid releasing live adenovirus in upper respiratory tract |
| Adhansia XR (Methylphenidate) | Capsule | Extended release. Capsule may be opened, sprinkled onto a tablespoon of applesauce or yogurt, and consumed without chewing within 10 minutes |
| Advagraf (Tacrolimus) | Capsule | Extended release |
| Advicor (Niacin and Lovastatin) | Tablet | Variable release |
| Adzenys XR-ODT (Amphetamine) | Orally disintegrating tablet | Extended release; sublingual form _g |
| Aemcolo (Rifamycin) | Tablet | Delayed release; manufacturer recommendation |
| Afeditab CR (NIFEdipine) | Tablet | Extended release |
| Afinitor (Everolimus) | Tablet | Manufacturer recommendation; mucous membrane irritant; hazardous substance _e ; pharmacokinetic amorphous solid dispersion technology may be affected. |
| Aggrenox (Aspirin and Dipyridamole) | Capsule | Extended release. Capsule may be opened; contents include an aspirin tablet that may be chewed and dipyridamole pellets that may be sprinkled on applesauce. |

| Drug Product | Dosage Form | Reasons/Comments |
|--|-----------------|---|
| Akeega (Niraparib and Abiraterone Acetate) | Tablet | Manufacturer recommendation; caregivers who are or could be pregnant should wear gloves if handling tablets |
| Alavert Allergy and Sinus (Loratadine and Pseudoephedrine) | Tablet | Extended release |
| Alecensa (Alectinib) | Capsule | Manufacturer recommendation |
| Alkindi Sprinkle (Hydrocortisone) | Capsule | Oral granules contained within the capsule; do not crush or chew granules |
| Allegra-D (Fexofenadine and Pseudoephedrine) | Tablet | Extended release |
| ALPRAZolam XR | Tablet | Extended release |
| Altace (Ramipril) | Capsule | Manufacturer recommendation; capsule may be opened and contents mixed with 120 mL of water, apple juice, or applesauce |
| Altoprev (Lovastatin) | Tablet | Extended release |
| Alunbrig (Brigatinib) | Tablet | Manufacturer recommendation |
| Alvaiz (Eltrombopag) | Tablet | Manufacturer recommendation |
| Alyftrek (Vanzacaftor, Tezacaftor, and Deutivacaftor) | Tablet | Manufacturer recommendation |
| Ambien CR (Zolpidem) | Tablet | Extended release |
| Amitiza (Lubiprostone) | Capsule | Manufacturer recommendation |
| Amnesteem (ISOTretinoin) | Capsule | Mucous membrane irritant; teratogenic potential |
| Ampyra (Dalfampridine) | Tablet | Extended release |
| Amrix (Cyclobenzaprine) | Capsule | Extended release |
| Aplenzin (BuPROPion) | Tablet | Extended release |
| Apriso (Mesalamine) | Capsule | Extended release |
| Aptensio XR (Methylphenidate) | Capsule | Slow release. Capsule may be opened, sprinkled onto a tablespoon of applesauce or yogurt, and consumed without chewing within 10 minutes. |
| Aptivus (Tiplranavir) | Capsule | Taste. Oil emulsion within spheres |
| Arakoda (Tafenoquine) | Tablet | Manufacturer recommendation |
| Aricept 23 mg (Donepezil) | Tablet | Film-coated; chewing or crushing may increase rate of absorption |
| Arava (Leflunomide) | Tablet | Teratogenic potential; hazardous substance _k |
| Arthrotec (Diclofenac and Misoprostol) | Tablet | Delayed release; enteric-coated |
| Arymo ER (Morphine) | Tablet | Slow release; tablet disruption may cause a potentially fatal overdose. |
| Asacol HD (Mesalamine) | Tablet | Slow release |
| Aspirin enteric-coated | Capsule, tablet | Delayed release; enteric-coated |
| Astagraf XL (Tacrolimus) | Capsule | Extended release; pharmacokinetic amorphous solid dispersion technology may be affected |
| Atelvia (Risedronate) | Tablet | Extended release; tablet coating is an important part of the delayed release |
| Augmentin XR (Amoxicillin and Clavulanate) | Tablet | Extended release _{b,h} |

| Drug Product | Dosage Form | Reasons/Comments |
|---|-------------|---|
| Augtyro (Repotrectinib) | Capsule | Manufacturer recommendation |
| Auryxia (Ferric Citrate) | Tablet | May cause discoloration of mouth and teeth |
| Austedo (Deutetrabenazine) | Tablet | Manufacturer recommendation |
| Austedo XL (Deutetrabenazine) | Tablet | Extended release |
| Auvelity (Dextromethorphan and Bupropion) | Tablet | Extended release |
| Ayvakt (Avapritinib) | Tablet | Canadian manufacturer recommendation (not in US labeling) |
| Avelox (Moxifloxacin) | Tablet | Canadian manufacturer recommendation (not in US labeling) |
| Avodart (Dutasteride) | Capsule | Mucus membrane irritation; capsule should not be handled by pregnant women due to teratogenic potential _j ; hazardous substance _k |
| Avmapki (Avutometinib) | Capsule | Manufacturer recommendation |
| Azulfidine EN-tabs (SulfaSALAZine) | Tablet | Delayed release |
| Bafiertam (Monomethyl fumarate) | Capsule | Delayed release |
| Balcoltra (Ethinyl Estradiol and Levonorgestrel) | Tablet | Hazardous agent |
| Balversa (Erdafitinib) | Tablet | Manufacturer recommendation |
| Bayer Aspirin (Aspirin) | Tablet | Delayed release |
| Bayer Aspirin, EC Low Dose 81 mg (Aspirin) | Tablet | Delayed release |
| Bayer Aspirin, Regimen Adult Low Strength 81 mg (Aspirin) | Tablet | Enteric coated |
| Bayer Aspirin, Regimen Regular Strength 325 mg (Aspirin) | Caplet | Enteric-coated |
| Belbuca (Buprenorphine) | Buccal film | Sublingual form _g ; chewing or swallowing may result in lower bioavailability |
| Belsomra (Suvorexant) | Tablet | Pharmacokinetic amorphous solid dispersion technology may be affected |
| Benzonatate | Capsule | Swallow whole; pharmacologic action may cause choking if chewed or opened and swallowed |
| Biaxin XL (Clarithromycin) | Tablet | Extended release |
| Biltricide (Praziquantel) | Tablet | Taste _h |
| Binosto (Alendronate) | Tablet | Effervescent tablet _f |
| Biphentin (Methylphenidate) | Capsule | Controlled release |
| Bisac-Evac (Bisacodyl) | Tablet | Enteric-coated _c |
| Bisacodyl | Tablet | Enteric-coated _c |
| Boniva (Ibandronate) | Tablet | Irritant. Chewed, crushed, or sucked tablets may cause oropharyngeal irritation |
| Bonjesta (Doxylamine and Pyridoxine) | Tablet | Controlled release |
| Bosulif (Bosutinib) | Tablet | Manufacturer recommendation; hazardous substance _k |
| Brincidofovir | Tablet | Manufacturer recommendation; hazardous substance _k |

| Drug Product | Dosage Form | Reasons/Comments |
|---|-----------------|---|
| Brenzavvy (Bexagliflozin) | Tablet | Manufacturer recommendation |
| Briviact (Brivaracetam) | Tablet | Film-coated _b ; manufacturer recommendation |
| Brukinsa (Zanubrutinib) | Capsule, tablet | Manufacturer recommendation; tablet is scored and may be split in half |
| Bunavail (Buprenorphine and Naloxone) | Buccal film | Chewing or swallowing may result in lower peak concentrations and bioavailability |
| Buprenorphine and Naloxone Sublingual | Tablet | Sublingual form _g |
| Buproban (BuPROPion) | Tablet | Extended release |
| BuPROPion SR | Tablet | Extended release |
| BuPROPion XL | Tablet | Extended release |
| Bylvay (Odevixibat) | Capsule | Manufacturer recommendation _a |
| Cabometyx (Cabozantinib) | Tablet | Manufacturer recommendation; film-coated; hazardous substance _k |
| Calan SR (Verapamil) | Tablet | Extended release _h |
| Calquence (Acalabrutinib) | Capsule | Manufacturer recommendation |
| Campral (Acamprosate) | Tablet | Delayed release; enteric-coated |
| Caprelsa (Vandetanib) | Tablet | Manufacturer recommendation _n ; irritant; hazardous substance _k |
| Carbaglu (Carglumic Acid) | Tablet | Tablets should be dispersed completely in water |
| Carbatrol (CarBAMazepine) | Capsule | Extended release _a |
| Cardizem CD (Diltiazem) | Capsule | Extended release |
| Cardizem LA (Diltiazem) | Tablet | Extended release |
| Cardura XL (Doxazosin) | Tablet | Extended release |
| Cartia XT (Diltiazem) | Capsule | Extended release |
| Casodex (Bicalutamide) | Tablet | Hazardous substance _k |
| Cefaclor ER | Tablet | Extended release |
| Ceftin (Cefuroxime) | Tablet | Taste _b . Use suspension for children |
| Cefuroxime | Tablet | Taste _b . Use suspension for children |
| CellCept (Mycophenolate) | Capsule, tablet | Teratogenic potential; hazardous substance _{i,k} |
| Cerdelga (Eliglustat) | Capsule | Preferably taken with water |
| Cesamet (Nabilone) | Capsule | Pharmacokinetic amorphous solid dispersion technology may be affected |
| Chlor-Trimeton Allergy (Chlorpheniramine) | Tablet | Extended release _b |
| Chlorpheniramine ER | Tablet | Extended release _b |
| Cholbam (Cholic Acid) | Capsule | Capsules may be opened and the contents mixed with food/drink. |
| Cibinqo (Abrocitinib) | Tablet | Manufacturer recommendation |
| Ciprofloxacin XL | Tablet | Extended release _b |
| Claravis (ISOTretinoin) | Capsule | Mucous membrane irritant; teratogenic potential |
| Claritin-D 12-Hour (Loratadine and Pseudoephedrine) | Tablet | Extended release |

| Drug Product | Dosage Form | Reasons/Comments |
|---|------------------------------|---|
| Claritin-D 24-Hour (Loratadine and Pseudoephedrine) | Tablet | Extended release |
| Codeine Contin (Codeine) | Tablet | Controlled release |
| Colace (Docusate) | Capsule | Taste _e |
| Colazal (Balsalazide) | Capsule | Manufacturer recommendation; contents may be sprinkled on applesauce and mixture may be chewed |
| Colestid (Colestipol) | Tablet | Slow release |
| Cometriq (Cabozantinib) | Capsule | Manufacturer recommendation; hazardous substance _k |
| Concerta (Methylphenidate) | Tablet | Extended release |
| Contrave (Naltrexone and Bupropion) | Tablet | Extended release |
| ConZip (TraMADol) | Capsule | Variable release; tablet disruption may cause overdose |
| Copiktra (Duvelisib) | Capsule | Manufacturer recommendation |
| Coreg CR (Carvedilol) | Capsule | Extended release _a ; may add contents to chilled applesauce and consume immediately. |
| CoreMino (Minocycline) | Tablet | Extended release |
| Cotazym (Pancrelipase) | Capsule | Enteric-coated _a |
| Cotellic (Cobimetinib) | Tablet | In the clinical trial, tablets were administered whole; do not chew, cut, or crush |
| Cotempla XR-ODT (Methylphenidate) | Orally disintegrating tablet | Extended release; orally disintegrating tablet designed to disintegrate on the tongue |
| Creon (Pancrelipase) | Capsule | Extended release _a ; enteric-coated contents |
| Cresemba (Isavuconazium) | Capsule | Manufacturer recommendation |
| Crixivan (Indinavir) | Capsule | Taste. Capsule may be opened and mixed with fruit puree (e.g., banana). |
| Cuvrior (Trientine Tetrahydrochloride) | Tablet | Manufacturer recommendation; scored tablet may be split in half if needed. |
| CycloPHOSphamide | Capsule, tablet | Hazardous substance _k ; manufacturer recommendation |
| Cymbalta (DULoxetine) | Capsule | Delayed release _a ; may add contents to apple juice or applesauce but not chocolate |
| Danziten (Nilotinib) | Tablet | Manufacturer recommendation |
| Dartisla-ODT (Glycopyrrolate) | Orally disintegrating tablet | Orally disintegrating tablet designed to disintegrate on the tongue |
| Daurismo (Glasdegib) | Tablet | Manufacturer recommendation |
| Delzicol (Mesalamine) | Capsule | Slow release _a |
| Depakene (Valproic Acid) | Capsule | Slow release; mucous membrane irritant _b ; hazardous substance _k |
| Depakote (Divalproex) | Tablet | Delayed release; hazardous substance _k |
| Depakote ER (Divalproex) | Tablet | Extended release; hazardous substance _k |
| Depakote Sprinkles (Divalproex) | Capsule | Delayed release _a ; hazardous substance _k |
| Detrol LA (Tolterodine) | Capsule | Extended release |
| Dexedrine (Dextroamphetamine) | Capsule | Extended release |
| Dexilant (Dexlansoprazole) | Capsule | Delayed release _a |

| Drug Product | Dosage Form | Reasons/Comments |
|--|-------------|--|
| Diacomit (Stiripentol) | Capsule | Manufacturer recommendation _i |
| Diamicron MR (Gliclazide) | Tablet | Modified release; may split 60 mg modified release tablets in half; 30 mg modified release tablets must be swallowed whole |
| Diamox Sequels (AcetaZOLAMIDE) | Capsule | Extended release |
| Dibenzylamine (Phenoxybenzamine) | Capsule | Hazardous substance _k |
| Diclegis (Doxylamine and Pyridoxine) | Tablet | Delayed release; manufacturer recommendation |
| Diflunisal | Tablet | Manufacturer recommendaton |
| DiltiaZEM | Capsule | Extended release |
| Dilt-XR (DiltiaZEM) | Capsule | Extended release |
| Ditropan XL (OxyBUTYnin) | Tablet | Extended release |
| Divalproex ER | Tablet | Extended release |
| Doryx (Doxycycline) | Tablet | Delayed release; tablet may be crushed without damaging or crushing delayed-release pellets |
| Doryx MPC (Doxycycline) | Tablet | Delayed release |
| Drisdol (Ergocalciferol) | Capsule | Liquid filled _d |
| Drizalma Sprinkle (DULoxetine) | Capsule | Delayed release _a |
| Droxia (Hydroxyurea) | Capsule | Manufacturer recommendation _j ; hazardous substance _k |
| Duavee (Estrogens [Conjugated/ Equine] and Bazedoxifene) | Tablet | Manufacturer recommendation; hazardous substance _k |
| Duexis (Ibuprofen and Famotidine) | Tablet | Manufacturer recommendation |
| Dulcolax (Bisacodyl) | Capsule | Liquid-filled |
| Dulcolax (Bisacodyl) | Tablet | Enteric-coated _c |
| Durlaza (Aspirin) | Capsule | Extended release |
| EC-Naprosyn (Naproxen) | Tablet | Delayed release; enteric-coated |
| Ecotrin Arthritis Strength (Aspirin) | Tablet | Enteric-coated |
| Ecotrin (Aspirin) | Tablet | Enteric-coated |
| Ecotrin Low Strength (Aspirin) | Tablet | Enteric-coated |
| Edluar (Zolpidem) | Tablet | Sublingual form _g |
| E.E.S. (Erythromycin) | Tablet | Enteric-coated _b |
| Effer-K (Potassium Bicarbonate and Potassium Citrate) | Tablet | Effervescent tablet _f |
| Effervescent Potassium | Tablet | Effervescent tablet _f |
| Effexor XR (Venlafaxine) | Capsule | Extended release _a |
| Elepsia XR (LevETIRAcetam) | Tablet | Extended release |
| Emend (Aprepitant) | Capsule | Manufacturer recommendation; pharmacokinetic NanoCrystal technology may be affected |
| Emrosi (Minocycline) | Capsule | Extended release |
| Enablex (Darifenacin) | Tablet | Slow release |
| Ensacove (Ensartinib) | Capsule | Manufacturer recommendation |
| Entocort EC (Budesonide) | Capsule | Extended release; enteric-coated _a |

| Drug Product | Dosage Form | Reasons/Comments |
|--------------------------------------|----------------------------|--|
| Envarsus PA | Tablet | Extended release |
| Envarsus XR (Tacrolimus) | Tablet | Extended release |
| Epclusa (Sofosbuvir and Velpatasvir) | Tablet | Pharmacokinetic amorphous solid dispersion technology may be affected |
| Equetro (CarBAMazepine) | Capsule | Extended release _a |
| Ergomar (Ergotamine) | Tablet | Sublingual form _g |
| Erivedge (Vismodegib) | Capsule | Manufacturer recommendation; hazardous substance _k |
| Erleada (Apalutamide) | Tablet | Manufacturer recommendation |
| Eryc (Erythromycin) | Capsule | Enteric-coated _a |
| Ery-Tab (Erythromycin) | Tablet | Delayed release; enteric-coated |
| Erythromycin Base | Tablet | Enteric-coated |
| Erythromycin Delayed Release | Capsule | Enteric-coated pellets _a |
| Erythromycin Ethylsuccinate | Tablet | Taste _b |
| Erythromycin Stearate | Tablet | Enteric-coated |
| Etoposide | Capsule | Hazardous substance _k |
| Etrasimod | Tablet | Manufacturer recommendation |
| Evekeo ODT (Amphetamine) | Oral disintegrating tablet | Sublingual form _g |
| Evista (Raloxifene) | Tablet | Taste; teratogenic potential _j ; hazardous substance _k |
| Evryssi (Risdiplam) | Tablet | Film-coated; tablet may be dispersed in nonchlorinated water |
| Exelon (Rivastigmine) | Capsule | Canadian manufacturer recommendation |
| Exjade (Deferasirox) | Tablet | Do not chew or swallow whole; do not give as tablets meant to be given as a liquid |
| Exkivity (Mobocertinib) | Capsule | Manufacturer recommendation |
| Exservan (Riluzole) | Film | Sublingual form _g |
| Ezallor Sprinkle (Rosuvastatin) | Capsule | Manufacturer recommendation _a |
| Fabhalta (Iptacopan) | Capsule | Manufacturer recommendation |
| Fareston (Toremifene) | Tablet | Hazardous substance _k |
| Farydak (Panobinostat) | Capsule | Manufacturer recommendation; hazardous substance _k |
| Feldene (Piroxicam) | Capsule | Mucous membrane irritant |
| Felodipine | Tablet | Extended release |
| FentaNYL | Lozenge | Slow release; lollipop delivery system requires the patient to slowly dissolve in mouth |
| Fentora (FentaNYL) | Tablet | Buccal tablet; swallowing whole or crushing may reduce effectiveness |
| Ferrous Sulfate | Tablet | Delayed release _b |
| Fetzima (Levomilnacipran) | Capsule | Extended release |
| Fexinidazole | Tablet | Manufacturer recommendation |
| Fibricor (Fenofibric Acid) | Tablet | Manufacturer recommendation |
| Fleet Laxative (Bisacodyl) | Tablet | Enteric-coated _c |
| Flomax (Tamsulosin) | Capsule | Slow release; manufacturer recommendation. Capsules may be opened and contents mixed with food (e.g., yogurt or pudding) or juice; refer to drug monograph for detailed recommendations. |

| Drug Product | Dosage Form | Reasons/Comments |
|--|-------------|--|
| Fludara (Fludarabine) | Tablet | Manufacturer (Canadian) recommendation; hazardous substance _k |
| FLUoxetine Weekly | Capsule | Delayed release |
| FluvoxaMINE ER | Capsule | Slow release |
| Focalin XR (Dexmethylphenidate) | Capsule | Extended release _a |
| Forfivo XL (BuPROPion) | Tablet | Extended release |
| Fortamet (MetFORMIN) | Tablet | Extended release |
| Fosamax (Alendronate) | Tablet | Mucous membrane irritant |
| Fosamax Plus D (Alendronate and Cholecalciferol) | Tablet | Mucous membrane irritant |
| Fotivda (Tivozanib) | Capsule | Manufacturer recommendation |
| Fruzaqla (Fruquintinib) | Capsule | Manufacturer recommendation |
| Galafold (MigALAsta) | Capsule | Manufacturer recommendation |
| Galzin (Zinc Acetate) | Capsule | Manufacturer recommendation _i ; possible gastric irritation |
| Gengraf (CycloSPORINE) | Capsule | Teratogenic potential; hazardous substance _k |
| Geodon (Ziprasidone) | Capsule | Hazardous substance _k |
| Gepirone (Exxua) | Tablet | Extended release |
| Gilotrif (Afatinib) | Tablet | Canadian manufacturer recommendation (not in US labeling); hazardous substance _k |
| Gleevec (Imatinib) | Tablet | Manufacturer recommendation _n ; mucous membrane irritant; hazardous substance _k |
| Gleostine (Lomustine) | Capsule | Manufacturer recommendation; hazardous substance _k |
| GlipiZIDE XL | Tablet | Extended release |
| Glucophage XR (MetFORMIN) | Tablet | Extended release |
| Glucotrol XL (GlipiZIDE) | Tablet | Extended release |
| Glumetza (MetFORMIN) | Tablet | Extended release |
| Gocovri (Amantadine) | Capsule | Extended release _a |
| Gomekli (Mirdametinib) | Capsule | Manufacturer recommendation |
| Gomekli (Mirdametinib) | Tablet | Manufacturer recommendation; tablet may be swallowed whole or (for patients unable to swallow whole) an oral suspension may be prepared from tablet(s) |
| Gralise (Gabapentin) | Tablet | Extended release _b |
| GuaiFENesin and Pseudoephedrine | Tablet | Slow release |
| Halfprin (Aspirin) | Tablet | Enteric-coated |
| Harvoni (Ledipasvir and Sofosbuvir) | Tablet | Pharmacokinetic amorphous solid dispersion technology may be affected |
| Hernexeos (Zongertinib) | Tablet | Manufacturer recommendation |
| Hetlioz (Tasimelteon) | Capsule | Manufacturer recommendation |
| Holkira Pak (Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir) | Tablet | Canadian manufacturer recommendation |
| Horizant (Gabapentin) | Tablet | Extended release _b |
| Hycamtin (Topotecan) | Capsule | Manufacturer recommendation; hazardous substance _k |

| Drug Product | Dosage Form | Reasons/Comments |
|--|-----------------|---|
| Hydrea (Hydroxyurea) | Capsule | Manufacturer recommendation _o ; hazardous substance _k |
| HYDROcodone | Capsule | Extended release; capsule disruption may cause a potentially fatal overdose |
| Hydromorph Contin (HYDROmorphone) | Capsule | Extended release |
| Hydromorphone ER | Tablet | Extended release |
| Hysingla ER (HYDROcodone) | Tablet | Extended release; tablet disruption may cause a potentially fatal overdose |
| Ibrance (Palbociclib) | Capsule, tablet | Manufacturer recommendation |
| Ibsrela (Tenapanor) | Tablet | Canadian manufacturer recommendation (not in US labeling) |
| Ibuprofen (Ibuprofen) | Capsule | Manufacturer recommendation |
| Iclusig (PONATinib) | Tablet | Manufacturer recommendation; hazardous substance _k |
| Idhifa (Enasidenib) | Tablet | Manufacturer recommendation |
| Imbruvica (Ibrutinib) | Capsule, tablet | Manufacturer recommendation _o |
| Imdur (Isosorbide Mononitrate) | Tablet | Extended release _n |
| Imitrex (SUMAtriptan) | Tablet | Manufacturer recommendation |
| Impavido (Miltefosine) | Capsule | Hazardous substance _k |
| Inderal LA (Propranolol) | Capsule | Extended release |
| Indomethacin ER | Capsule | Extended release _{b,c} |
| Ingrezza Sprinkle (Valbenazine) | Capsule | Manufacturer recommendation; capsule may be opened and the contents sprinkled on soft food (e.g., applesauce, pudding, yogurt); granules should not be chewed or crushed. Do not administer via gastrostomy, nasogastric, or other enteral tubes. |
| Inlyta (Axitinib) | Tablet | Manufacturer recommendation _o ; hazardous substance _k |
| Inluriyo (Imlunestrant) | Tablet | Manufacturer recommendation |
| InnoPran XL (Propranolol) | Capsule | Extended release |
| Inpefa (Sotagliflozin) | Tablet | Manufacturer recommendation |
| Inqovi (Decitabine and Cedazuridine) | Tablet | Manufacturer recommendation; hazardous substance _k |
| Intelence (Etravirine) | Tablet | Pharmacokinetic amorphous solid dispersion technology may be affected. Tablet should be swallowed whole and not crushed; tablet may be dispersed in water. |
| Intuniv (GuanFACINE) | Tablet | Extended release |
| Invega (Paliperidone) | Tablet | Extended release |
| Invokamet XR (Canagliflozin and Metformin) | Tablet | Extended release |
| Invokana (Canagliflozin) | Tablet | Canadian manufacturer recommendation |
| Iressa (Gefitinib) | Tablet | Note: Tablet may be dissolved in 120 to 240 mL of water |
| Isoptin SR (Verapamil) | Tablet | Extended release _{n,r} ; pharmacokinetic amorphous solid dispersion technology may be affected |
| Isosorbide Mononitrate ER | Tablet | Extended release |
| ISOTretinoin | Capsule | Mucous membrane irritant; teratogenic potential |
| Isradipine | Capsule | Slow release |
| Itovebi (Inavolisib) | Tablet | Manufacturer recommendation |

| Drug Product | Dosage Form | Reasons/Comments |
|---|-------------|---|
| Jakavi (Ruxolitinib) | Tablet | Canadian manufacturer recommendation (not in US labeling) _n |
| Jalyn (Dutasteride and Tamsulosin) | Capsule | Mucous membrane irritant; capsule should not be handled by pregnant women due to teratogenic potential _j ; hazardous substance _{i,k} |
| Janumet XR (Sitagliptin and Metformin) | Tablet | Extended release _a |
| Jaypirca (Pirtobrutinib) | Tablet | Manufacturer recommendation |
| Jentadueto XR (Linagliptin and Metformin) | Tablet | Extended release |
| Jesduvroq (Daprodustat) | Tablet | Manufacturer recommendation |
| Jornay PM (Methylphenidate) | Capsule | Extended release _a |
| Juxtapid (Lomitapide) | Capsule | Manufacturer recommendation |
| Kadian (Morphine) | Capsule | Extended release _a ; Do not give via NG tubes; may add contents to applesauce without crushing. Capsule disruption may cause a potentially fatal overdose. |
| Kaletra (Lopinavir and Ritonavir) | Tablet | Film-coated; pharmacokinetic amorphous solid dispersion technology may be affected; pregnant women or women who may become pregnant should not handle crushed or broken tablets; active ingredients surrounded by wax matrix to prevent health care exposure. |
| Kalydeco (Ivacaftor) | Tablet | Pharmacokinetic amorphous solid dispersion technology may be affected |
| Kaspargo Sprinkle (Metoprolol) | Capsule | Extended release _a |
| Kapvay (CloNIDine) | Tablet | Extended release |
| Kazano (Alogliptin and Metformin) | Tablet | Not scored; manufacturer recommendation _l |
| K-Dur (Potassium Chloride) | Tablet | Slow release _b |
| Keppra (LevETIRAcetam) | Tablet | Taste _{b,e} |
| Keppra XR (LevETIRAcetam) | Tablet | Extended release _b |
| Ketoprofen ER | Capsule | Extended release |
| Khedezla (Desvenlafaxine) | Tablet | Extended release |
| Kisqali (Ribociclib) | Tablet | Manufacturer recommendation |
| Kisqali Femara Co-Pack (Ribociclib and Letrozole) | Tablet | Manufacturer recommendation (ribociclib); hazardous substance (letrozole) _k |
| Klor-Con (Potassium Chloride) | Tablet | Extended release _b |
| Klor-Con M (Potassium Chloride) | Tablet | Slow release _b ; some strengths are scored; to make liquid, place tablet in 120 mL of water; disperse 2 minutes; stir |
| Klor-Con Sprinkle | Capsule | Extended release |
| Kombiglyze XR (Saxagliptin and Metformin) | Tablet | Extended release; tablet matrix may remain in stool |
| Korlym (Mifepristone) | Tablet | Reproductive toxicity; hazardous substance _k |
| Koselugo (Selumetinib) | Capsule | Manufacturer recommendation |
| Krazati (Adagrasib) | Tablet | Manufacturer recommendation |
| Krintafel (Tafenoquine) | Tablet | Manufacturer recommendation |
| K-Tab (Potassium Chloride) | Tablet | Extended release _b |

| Drug Product | Dosage Form | Reasons/Comments |
|--|-------------|--|
| LaMICTal XR (Lamotrigine) | Tablet | Extended release |
| Latuda (Lurasidone) | Tablet | Manufacturer recommendation _i |
| Lazcluze (Lazertinib) | Tablet | Manufacturer recommendation |
| Lenvima (Lenvatinib) | Capsule | Manufacturer recommendation; may dissolve in a small glass of liquid |
| Lescol XL (Fluvastatin) | Tablet | Extended release |
| Letairis (Ambrisentan) | Tablet | Film-coated; hazardous substance _k |
| Leukeran (Chlorambucil) | Tablet | Hazardous substance _{k,o} |
| Levbid (Hyoscyamine) | Tablet | Extended release _n |
| Lialda (Mesalamine) | Tablet | Delayed release, enteric-coated |
| Linzess (Linaclotide) | Capsule | Manufacturer recommendation _a |
| Lipidil EZ (Fenofibrate) | Tablet | Film-coated; manufacturer recommendation |
| Lipidil Supra (Fenofibrate) | Tablet | Film-coated; manufacturer recommendation |
| Lithium Carbonate ER | Tablet | Extended release |
| Lithobid (Lithium) | Tablet | Extended release |
| Lonsurf (Trifluridine and Tipiracil) | Tablet | Manufacturer recommendation; hazardous substance _k |
| Lorbrena (lorlatinib) | Tablet | Manufacturer recommendation |
| Lovaza (Omega-3 Fatty Acids) | Capsule | Contents of capsule may erode walls of styrofoam or plastic materials |
| Lumakras (Sotorasib) | Tablet | Manufacturer recommendation _n |
| Lupkynis (Voclosporin) | Capsule | Manufacturer recommendation |
| Lybalvi (Olanzapine and Samidorphan) | Tablet | Do not divide tablets |
| Lynparza (Olaparib) | Tablet | Manufacturer recommendation; pharmacokinetic amorphous solid dispersion technology may be affected |
| Lyrica CR (Pregabalin) | Tablet | Extended release |
| Lysodren (Mitotane) | Tablet | Manufacturer recommendation |
| Lytgobi (Futibatinib) | Tablet | Manufacturer recommendation |
| Macrobid (Nitrofurantoin) | Capsule | Manufacturer recommendation |
| Mag-Tab SR (Magnesium L-Lactate) | Tablet | Extended release |
| Matulane (Procarbazine) | Capsule | Hazardous substance _{k,n} |
| Mavenclad (Cladribine) | Tablet | Manufacturer recommendation; hazardous substance _k |
| Mavyret (Glecaprevir and Pibrentasvir) | Tablet | Pharmacokinetic amorphous solid dispersion technology may be affected |
| Mayzent (Siponimod) | Tablet | Film-coated; manufacturer recommendation |
| Mekinist (Trametinib) | Tablet | Manufacturer recommendation |
| Mestinon ER (PyRIDostigmine) | Tablet | Extended release _b |
| Metadate CD (Methylphenidate) | Capsule | Extended release _a |
| Methylphenidate (AB rated generics to Methylin ER) | Tablet | Slow release |
| Metoprolol Succinate ER | Tablet | Extended release |
| Mezavant | Tablet | Delayed release |

| Drug Product | Dosage Form | Reasons/Comments |
|---|--|---|
| Mezera (Mesalamine) | Tablet | Delayed release |
| Micro-K (Potassium Chloride) | Capsule | Extended release _{a,b} |
| Minolira (Minocycline) | Tablet | Extended release _h |
| Mirapex ER (Pramipexole) | Tablet | Extended release |
| Morphine Sulfate Extended Release | Capsules (once-daily formulation [pellets]) | Extended release _a ; Do not give via gastric/NG tubes; may add contents to applesauce without crushing. Capsule disruption may cause a potentially fatal overdose. |
| Morphine Sulfate Extended Release | Capsules (once- or twice-daily formulation [polymer coated pellets]) | Extended release _a ; Do not give via NG tubes; may add contents to applesauce without crushing. Capsule disruption may cause a potentially fatal overdose. |
| Morphine Sulfate Extended Release | Tablet | Extended release _b ; tablet disruption may cause a potentially fatal overdose |
| Motpoly XR (Lacosamide) | Capsule | Extended release _b |
| Motrin (Ibuprofen) | Tablet | Taste _{b,e} |
| MS Contin (Morphine) | Tablet | Extended release _b ; tablet disruption may cause a potentially fatal overdose |
| Mucinex (GuaiFENesin) | Tablet | Slow release |
| Mucinex DM (GuaiFENesin) | Tablet | Slow release _b |
| Multaq (Dronedarone) | Tablet | Hazardous substance _k |
| Mycapssa (Octreotide) | Capsule | Delayed release |
| Mydayis (Dextroamphetamine and Amphetamine) | Capsule | Extended release _a |
| Myfortic (Mycophenolate) | Tablet | Delayed release; enteric-coated; teratogenic potential; hazardous substance _k |
| Myorisan (ISOTretinoin) | Capsule | Mucous membrane irritant; teratogenic potential |
| Myrbetriq (Mirabegron) | Tablet | Extended release |
| Mytesi (Crofelemer) | Tablet | Delayed release |
| Namenda XR (Memantine) | Capsule | Extended release _{a,b} |
| Namzaric (Memantine and Donepezil) | Capsule | Slow release _a |
| Naprelan (Naproxen) | Tablet | Extended release |
| Neoral (CycloSPORINE) | Capsule | Teratogenic potential; hazardous substance _k |
| Nerlynx (Neratinib) | Tablet | Manufacturer recommendation |
| Nesina (Alogliptin) | Tablet | Film-coated; manufacturer recommendation |
| Neurontin (Gabapentin) | Capsule | ISMP recommendation _b |
| Neurontin (Gabapentin) | Tablet | ISMP recommendation _h |
| NexIUM (Esomeprazole) | Capsule | Delayed release _a |
| Niacin | Capsule, tablet | Extended release |
| Niaspan (Niacin) | Tablet | Extended release |
| Nifedical XL (NIFEdipine) | Tablet | Extended release |
| NIFEdipine ER | Tablet | Extended release |
| Nimotop (Nimodipine) | Tablet | Canadian manufacturer recommendation |

| Drug Product | Dosage Form | Reasons/Comments |
|-------------------------------------|------------------------------|--|
| Ninlaro (Ixazomib) | Capsule | Hazardous substance _k ; manufacturer recommendation |
| Nitrostat (Nitroglycerin) | Tablet | Sublingual route _g |
| Nocdurna (Desmopressin) | Tablet | Sublingual route _g |
| Norpace CR (Disopyramide) | Capsule | Extended release; form within a special capsule |
| Northera (Droxidopa) | Capsule | Manufacturer recommendation |
| Norvir (Ritonavir) | Tablet | Manufacturer recommendation; crushing tablets has resulted in decreased bioavailability of drug _b ; pharmacokinetic amorphous solid dispersion technology may be affected |
| Noxafil (Posaconazole) | Tablet | Delayed release _b ; pharmacokinetic amorphous solid dispersion technology may be affected |
| Nubeqa (Darolutamide) | Tablet | Manufacturer recommendation |
| Nucynta ER (Tapentadol) | Tablet | Extended release; tablet disruption may cause a potentially fatal overdose |
| Nurtec ODT (Rimegepant) | Orally disintegrating tablet | Orally disintegrating _g |
| Octasa (Mesalamine) | Tablet | Delayed release |
| Ofev (Nintedanib) | Capsule | Taste |
| Ogsiveo (Nirogacestat) | Tablet | Manufacturer recommendation |
| Ojemda (Tovorafenib) | Tablet | Manufacturer recommendation |
| Ojjaara (Momelotinib) | Tablet | Manufacturer recommendation |
| Omtryg (Omega-3 Fatty Acids) | Capsule | Manufacturer recommendation; contents of capsule may be erosive |
| Onglyza (SAXagliptin) | Tablet | Manufacturer recommendation |
| Onureg (AzaCITIDine) | Tablet | Manufacturer recommendation; hazardous substance _k |
| Opsumit (Macitentan) | Tablet | Teratogenic potential; hazardous substance _k |
| Opsynvi (Macitentan and Tadalafil) | Tablet | Film coated; teratogenic potential; hazardous substance _k |
| Oracea (Doxycycline) | Capsule | Delayed release |
| Orapred ODT (PrednisolONE) | Orally disintegrating tablet | Orally disintegrating. Do not break, cut, split, or use partial tablet; may swallow whole or allow tablet to dissolve on tongue. |
| Oravig (Miconazole) | Buccal tablet | Buccal form |
| Orenitram (Trepstinil) | Tablet | Slow release |
| Orgovyx (Relugolix) | Tablet | Manufacturer recommendation |
| Orkambi (Lumacaftor and Ivacaftor) | Tablet | Pharmacokinetic amorphous solid dispersion technology may be affected |
| Orphenadrine Citrate ER | Tablet | Extended release |
| Ortikos (Budesonide) | Capsule | Extended release |
| Oseni (Alogliptin and Pioglitazone) | Tablet | Manufacturer recommendation _i |
| Oserdu (Elacestrant) | Tablet | Manufacturer recommendation |
| Osmolex ER (Amantadine) | Tablet | Extended release _b |
| Otezla (Apremilast) | Tablet | Manufacturer recommendation; film-coated |
| Oxaydo (OxyCODONE) | Tablet | Not amenable to crushing; may obstruct feeding tubes _b |
| Oxtellar XR (OXcarbazepine) | Tablet | Extended release |

| Drug Product | Dosage Form | Reasons/Comments |
|---|-----------------------|--|
| OxyCONTIN (OxyCODONE) | Tablet | Extended release; surrounded by wax matrix; tablet disruption may cause a potentially fatal overdose |
| Oxy-IR (OxyCODONE) | Tablet | Canadian manufacturer recommendation |
| OxyMORphone ER | Tablet | Extended release |
| OxyNeo (OxyCODONE) | Tablet | Extended release |
| Pancreaze (Pancrelipase) | Capsule | Slow-release _a ; enteric-coated contents |
| Pancrelipase | Capsule | Slow-release _a ; enteric-coated contents |
| Paxil CR (PARoxetine) | Tablet | Extended release |
| Paxil (PARoxetine) | Tablet | Film-coated _b |
| Pemazyre (Pemigatinib) | Tablet | Manufacturer recommendation |
| Pentasa (Mesalamine) | Capsule | Extended release _a |
| Pertzye (Pancrelipase) | Capsule | Slow-release _a ; enteric-coated contents |
| Pexeva (PARoxetine) | Tablet | Film-coated _b |
| Phenytek (Phenytoin) | Capsule | Extended release; manufacturer recommendation _l |
| Piqray (Alpelisib) | Tablet | Film-coated; manufacturer recommendation |
| Plaquenil (Hydroxychloroquine) | Tablet | Manufacturer recommendation (for film-coated tablets) |
| Plendil (Felodipine) | Tablet | Extended release |
| Pomalyst (Pomalidomide) | Capsule | Manufacturer recommendation; teratogenic potential; hazardous substance _k |
| Ponvory (Ponesimod) | Tablet | Film-coated; manufacturer recommendation |
| Pradaxa (Dabigatran) | Capsule | Bioavailability increases by 75% when the pellets are taken without the capsule shell |
| Prevacid (Lansoprazole) | Capsule | Delayed release _a |
| Prevacid (Lansoprazole) | Suspension | Slow release. Contains enteric-coated granules. Not for use in NG tubes; mix with water only |
| Prevacid SoluTab (Lansoprazole) | Tablet | Orally disintegrating. Do not swallow; dissolve in water only and dispense via dosing syringe or NG tube |
| Prevpac (Lansoprazole, Amoxicillin, and Clarithromycin) | Capsule, tablet | Manufacturer recommendation |
| Prevymis (Letermovir) | Oral pellets, tablets | Manufacturer recommendation |
| PriLOSEC (Omeprazole) | Capsule | Delayed release _{a,b} |
| PriLOSEC OTC (Omeprazole) | Tablet | Delayed release |
| Pristiq (Desvenlafaxine) | Tablet | Extended release |
| Procardia (NIFEdipine) | Capsule | Pharmacokinetics may be altered if not taken whole |
| Procardia XL (NIFEdipine) | Tablet | Extended release |
| Procysbi (Cysteamine) | Capsule | Delayed release _a |
| Prograf (Tacrolimus) | Capsule | Pharmacokinetic amorphous solid dispersion technology may be affected |
| Prolopa (Benserazide and Levodopa) | Capsule | Manufacturer recommendation |
| Promacta (eltrombopag) | Tablet | Manufacturer recommendation |

| Drug Product | Dosage Form | Reasons/Comments |
|--|-------------|---|
| Propecia (Finasteride) | Tablet | Women who are, or may become, pregnant should not handle crushed or broken tablets due to teratogenic potential; hazardous substance _k |
| Proscar (Finasteride) | Tablet | Women who are, or may become, pregnant should not handle crushed or broken tablets due to teratogenic potential; hazardous substance _k |
| Protonix (Pantoprazole) | Tablet | Slow release _b |
| Purinethol (Mercaptopurine) | Tablet | Teratogenic potential; hazardous substance _k |
| Pylera (Bismuth Subcitrate, Metronidazole, and Tetracycline) | Capsule | Mucous membrane irritant |
| Pyrukynd (Mitapivat) | Tablet | Manufacturer recommendation |
| Pytest (Carbon 14 Urea) | Capsule | Manufacturer recommendation; hazardous substance _k |
| Qelbree (Viloxazine) | Capsule | Extended release _a |
| Qinlock (Ripretinib) | Tablet | Manufacturer recommendation |
| Qtern (Dapagliflozin and Saxagliptin) | Tablet | Manufacturer recommendation |
| Qternmet XR (Dapagliflozin, Saxagliptin, and Metformin) | Tablet | Manufacturer recommendation |
| Qudexy XR (Topiramate) | Capsule | Extended release _a |
| QuiNIDine ER | Tablet | Extended release _n ; enteric-coated |
| Ranexa (Ranolazine) | Tablet | Slow release |
| Rapamune (Sirolimus) | Tablet | Manufacturer recommendation; hazardous substance _k ; pharmacokinetic NanoCrystal technology may be affected _b |
| Rayaldee (Calcifediol) | Capsule | Extended release |
| Rayos (PredniSONE) | Tablet | Delayed release _v ; release is dependent upon intact coating |
| Razadyne ER (Galantamine) | Capsule | Extended release |
| Rebetol (Ribavirin) | Capsule | Manufacturer recommendation; hazardous substance _k |
| Remeron SolTab (Mirtazapine) | Tablet | Orally disintegrating form _g |
| Renagel (Sevelamer) | Tablet | Manufacturer recommendation _v ; expands in liquid if broken/crushed. |
| Renvela (Sevelamer) | Tablet | Manufacturer recommendation _v ; expands in liquid if broken or crushed |
| Retevmo (Selpercatinib) | Capsule | Manufacturer recommendation |
| Revlimid (Lenalidomide) | Capsule | Manufacturer recommendation; teratogenic potential; hazardous substance _k |
| Revuforj (Revumenib) | Tablet | Manufacturer recommendation; tablets may be crushed and dispersed in water |
| Reyataz (Atazanavir) | Capsule | Oral powder is available; see prescribing information for administration instructions |
| Reyvow (Lasmiditan) | Tablet | Film-coated; manufacturer recommendation |
| Rezlidhia (Olutasidenib) | Capsule | Manufacturer recommendation |
| Rezurock (Belumosudil) | Tablet | Film-coated; manufacturer recommendation |
| Ribasphere (Ribavirin) | Capsule | Manufacturer recommendation |

| Drug Product | Dosage Form | Reasons/Comments |
|-------------------------------------|------------------------------|--|
| Rinvoq (Upadacitinib) | Tablet | Extended release |
| RisperiDONE M-Tab | Orally disintegrating tablet | Orally disintegrating. Do not chew or break tablet; after dissolving under tongue, tablet may be swallowed |
| Ritalin LA (Methylphenidate) | Capsule | Extended release _a |
| Ritalin-SR (Methylphenidate) | Tablet | Extended release |
| Romvimza (Vimseltinib) | Capsule | Manufacturer recommendation |
| ROPINIROLE ER | Tablet | Extended release |
| Roszet (Ezetimibe and Rosuvastatin) | Tablet | Manufacturer recommendation |
| Roweepra (Levetiracetam) | Tablet | Taste _b |
| Roweepra ER (Levetiracetam) | Tablet | Extended release _b |
| Rozlytrek (Entrectinib) | Capsule | Manufacturer recommendation |
| Rukobia (Fostemsavir) | Tablet | Extended release |
| Rybelsus (Semaglutide) | Tablet | Manufacturer recommendation |
| Rydapt (Midostaurin) | Capsule | Manufacturer recommendation |
| Rytary (Carbidopa and Levodopa) | Capsule | Extended release _a |
| Rythmol SR (Propafenone) | Capsule | Extended release |
| Salofalk (Mesalamine) | Tablet | Delayed release |
| SandIMMUNE (CycloSPORINE) | Capsule | Teratogenic potential; hazardous substance _k |
| Saphris (Asenapine) | Tablet | Sublingual form _g |
| Scemblix (Asciminib) | Tablet | Manufacturer recommendation |
| Sensipar (Cinacalcet) | Tablet | Tablets are not scored and cutting may cause inaccurate dosage |
| Seroquel XR (Quetiapine) | Tablet | Extended release |
| Siklos (Hydroxyurea) | Tablet | Manufacturer recommendation _n ; hazardous substance _k |
| Simcor (Niacin and Simvastatin) | Tablet | Tablet contains extended release niacin |
| Sinemet CR (Carbidopa and Levodopa) | Tablet | Extended release _n |
| Sirturo (Bedaquiline) | Tablet | Manufacturer recommendation _i |
| Sitavig (Acyclovir) | Tablet | Buccal tablet; swallowing whole or crushing eliminates or reduces effectiveness |
| Skyclarys (Omaveloxolone) | Capsule | Manufacturer recommendation; contents may be sprinkled onto two tablespoonsful of applesauce and consumed immediately. |
| Slo-Niacin (Niacin) | Tablet | Slow release _n |
| Slow Fe (Ferrous Sulfate) | Tablet | Extended release, manufacturer recommendation _b |
| Slow Iron (Ferrous Sulfate) | Tablet | Extended release, manufacturer recommendation _b |
| Slow-Mag (Magnesium Chloride) | Tablet | Delayed release |
| Slynd (Drospirenone) | Tablet | Manufacturer recommendation; hazardous substance |
| Solodyn (Minocycline) | Tablet | Extended release |
| Soriatane (Acitretin) | Capsule | Teratogenic potential; hazardous substance _k |
| Sotyktu (Deucravacitinib) | Tablet | Manufacturer recommendation |
| Sovuna (Hydroxychloroquine) | Tablet | Film coated; 300 mg tablet is scored and may be divided but not crushed |

| Drug Product | Dosage Form | Reasons/Comments |
|--|------------------------------|--|
| Sporanox (Itraconazole) | Capsule | Pharmacokinetic amorphous solid dispersion technology may be affected |
| Sprycel (Dasatinib) | Tablet | Film-coated. Manufacturer recommendation _r ; active ingredients are surrounded by a wax matrix to prevent health care exposure. Caregivers who are or could become pregnant should not handle crushed or broken tablets; hazardous substance _k |
| Stalevo (Levodopa, Carbidopa, and Entacapone) | Tablet | Manufacturer recommendation; combining multiple tablets or portions of tablets may lead to an overdose of entacapone |
| Staxyn (Verdenafil) | Orally disintegrating tablet | Sublingual form _g |
| Stivarga (Regorafenib) | Tablet | Manufacturer recommendation; hazardous substance _k ; pharmacokinetic amorphous solid dispersion technology may be affected |
| Strattera (AtoMOXetine) | Capsule | Capsule contents can cause ocular irritation |
| Suboxone (Buprenorphine and Naloxone) | Buccal film | Sublingual form _g |
| Sudafed 12-Hour (Pseudoephedrine) | Capsule | Extended release _b |
| Sudafed 24-Hour (Pseudoephedrine) | Capsule | Extended release _b |
| Sular (Nisoldipine) | Tablet | Extended release |
| Supeudol (OxyCODONE) | Tablet | Canadian manufacturer recommendation |
| Sustiva (Efavirenz) | Tablet | Manufacturer recommendation; tablets should not be broken (capsules should be used if dosage adjustment needed) |
| Symax Duotab (Hyoscyamine) | Tablet | Controlled release |
| Symax SR (Hyoscyamine) | Tablet | Extended release |
| Symbravo (Meloxicam and Rizatriptan) | Tablet | Manufacturer recommendation |
| Symdeko (Tezacaftor and Ivacaftor) | Tablet | Manufacturer recommendation _r ; pharmacokinetic amorphous solid dispersion technology may be affected |
| Synjardy XR (Empagliflozin and Metformin) | Tablet | Extended release |
| Syprine (Trientine) | Capsule | Manufacturer recommendation; potential risk of contact dermatitis |
| Tabloid (Thioguanine) | Tablet | Hazardous substance _{k,o} |
| Tabrecta (Capmatinib) | Tablet | Manufacturer recommendation |
| Tafinlar (Dabrafenib) | Capsule | Manufacturer recommendation; hazardous substance _k |
| Tafinlar (Dabrafenib) | Table for oral suspension | Do not chew, crush, or swallow whole; tablets for oral suspension are meant to be administered as a liquid |
| Tagrisso (Osimertinib) | Tablet | Note: May be dissolved in 60 mL of water |
| Talicia (Omeprazole, Amoxicillin, and Rifabutin) | Capsule | Manufacturer recommendation; delayed release |
| Talzenna (Talazoparib) | Capsule | Manufacturer recommendation |
| Tamoxifen | Tablet | Hazardous substance _{k,o} |
| Targin (Oxycodone and Naloxone) | Tablet | Extended release; tablet disruption may cause a potentially fatal overdose |
| Tarpeyo (Budesonide) | Capsule | Delayed release |

| Drug Product | Dosage Form | Reasons/Comments |
|--|-------------|--|
| Tasigna (Nilotinib) | Capsule | Manufacturer recommendation _n ; hazardous substance _k ; altering capsule may lead to high blood levels, increasing the risk of toxicity |
| Tavenos (Avacopan) | Capsule | Manufacturer recommendation |
| Taztia XT (Diltiazem) | Capsule | Extended release _a |
| Tazverik (Tazemetostat) | Tablet | Manufacturer recommendation |
| Tecfidera (Dimethyl Fumarate) | Capsule | Manufacturer recommendation; delayed release; irritant |
| Tegretol-XR (Carbamazepine) | Tablet | Extended release _b |
| Temodar (Temozolomide) | Capsule | Manufacturer recommendation _o ; hazardous substance _k . Note: If capsules are accidentally opened or damaged, rigorous precautions should be taken to avoid inhalation or contact of contents with the skin or mucous membranes. |
| Tepmetko (Tepotinib) | Tablet | Manufacturer recommendation; tablets may be dispersed in noncarbonated water without crushing |
| Tessalon Perles (Benzonatate) | Capsule | Swallow whole; pharmacologic action may cause choking if chewed or opened and swallowed. |
| Teva-Oxycodan (Oxycodone and Aspirin) | Tablet | Manufacturer recommendation |
| Thalomid (Thalidomide) | Capsule | Manufacturer recommendation _o ; teratogenic potential; hazardous substance _k |
| Theo-24 (Theophylline) | Capsule | Extended release _a ; contains beads that dissolve through GI tract |
| Theochron (Theophylline) | Tablet | Extended release |
| Theophylline ER | Tablet | Extended release |
| Tiazac (Diltiazem) | Capsule | Extended release _a |
| Tibsovo (Ivosidenib) | Tablet | Manufacturer recommendation; pharmacokinetic amorphous solid dispersion technology may be affected |
| Tirosint (Levothyroxine) | Capsule | Manufacturer recommendation; liquid-filled |
| Tolsura (Itraconazole) | Capsule | Manufacturer recommendation _b |
| Topamax Sprinkle (Topiramate) | Capsule | Taste _a |
| Topamax (Topiramate) | Capsule | Taste _a |
| Topamax (Topiramate) | Tablet | Taste |
| Toprol XL (Metoprolol Succinate) | Tablet | Extended release _n |
| Toviaz (Fesoterodine) | Tablet | Extended release |
| Tracleer (Bosentan) | Tablet | Teratogenic potential; hazardous substance _k ; women who are or may be pregnant should not handle crushed or broken tablets |
| TraMADol ER | Tablet | Extended release |
| Tranexamic Acid | Tablet | Manufacturer recommendation |
| Trental (Pentoxifylline) | Tablet | Extended release |
| Tretinoin | Capsule | Manufacturer recommendation _o |
| Treximet (Sumatriptan and Naproxen) | Tablet | Unique formulation enhances rapid drug absorption |
| TriCor (fenofibrate and derivatives) | Tablet | Pharmacokinetic NanoCrystal technology may be affected |
| Triglide (fenofibrate and derivatives) | Tablet | Pharmacokinetic NanoCrystal technology may be affected |

| Drug Product | Dosage Form | Reasons/Comments |
|---|-------------|---|
| Trijardy XR (Empagliflozin, Linagliptin, and Metformin) | Tablet | Extended release |
| Trikafta (Elexacaftor, Tezacaftor, and Ivacaftor) | Tablet | Manufacturer recommendation; pharmacokinetic amorphous solid dispersion technology may be affected |
| TriLipix (Fenofibrate) | Capsule | Extended release |
| Trokendi XR (Topiramate) | Capsule | Extended release |
| Trospium and Xanomeline (Cobenfy) | Capsule | Manufacturer recommendation; do not open |
| Trulance (Plecanatide) | Tablet | Manufacturer recommendation; see package insert for instructions on crushing administration |
| Truqap (Capivasertib) | Tablet | Manufacturer recommendation |
| Tukysa (Tucatinib) | Tablet | Manufacturer recommendation |
| Turalio (Pexidartinib) | Capsule | Manufacturer recommendation |
| Tylenol 8 Hour (Acetaminophen) | Caplet | Extended release |
| Uceris (Budesonide) | Tablet | Extended release; coating on tablet designed to break down at pH of ≥ 7 |
| Ultram ER (TraMADol) | Tablet | Extended release. Tablet disruption may cause a potentially fatal overdose. |
| Uniphyll (Theophylline) | Tablet | Slow release |
| Upravi (Selexipag) | Tablet | Manufacturer recommendation; film-coated |
| Urocit-K (Potassium Citrate) | Tablet | Wax-coated; prevents upper GI release |
| Uroxatral (Alfuzosin) | Tablet | Extended release |
| Urso Forte (Ursodiol) | Tablet | Tablet is scored and may be split |
| Vadadustat (Vafseo) | Tablet | Manufacturer recommendation; film-coated |
| Valcyte (ValGANCiclovir) | Tablet | Irritant potential _g ; teratogenic potential; hazardous substance _k |
| Vanflyta (Quizartinib) | Tablet | Manufacturer recommendation |
| Vanrafia (Atrasentan) | Tablet | Manufacturer recommendation |
| Vascepa (Omega-3 Fatty Acids) | Capsule | Manufacturer recommendation |
| Venclexta (Venetoclax) | Tablet | Manufacturer recommendation; film-coated; pharmacokinetic amorphous solid dispersion technology may be affected |
| Venlafaxine ER | Tablet | Extended release |
| Veozah (Fezolinetant) | Tablet | Film coated |
| Verapamil SR | Tablet | Extended release _n |
| Verelan (Verapamil) | Capsule | Sustained release _a |
| Verelan PM (Verapamil) | Capsule | Extended release _a |
| Verzenio (Abemaciclib) | Tablet | Manufacturer recommendation |
| VESIcare (Solifenacin) | Tablet | Manufacturer recommendation; taste |
| Videx EC (Didanosine) | Capsule | Delayed release; enteric-coated |
| Viekira XR (Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir) | Tablet | Extended release; pharmacokinetic amorphous solid dispersion technology may be affected |
| Vijoice (Alpelisib) | Tablet | Manufacturer recommendation _n |
| Vimovo (Naproxen and Esomeprazole) | Tablet | Delayed release |

| Drug Product | Dosage Form | Reasons/Comments |
|--|-------------------------|--|
| Vimpat (Lacosamide) | Tablet | Film-coated _{b,p} ; manufacturer recommendation |
| Viokace (Pancrelipase) | Tablet | Mucous membrane irritant _p |
| Viramune XR (Nevirapine) | Tablet | Extended release _b |
| Vitakvi (Larotrectinib) | Capsule | Manufacturer recommendation _b |
| Vivjoa (Oteseconazole) | Capsule | Manufacturer recommendation |
| Vivotif (Typhoid Vaccine) | Capsule | Manufacturer recommendation; enteric-coated |
| Voltaren-XR (Diclofenac) | Tablet | Extended release |
| Vonjo (Pacritinib) | Capsule | Manufacturer recommendation |
| Voranigo (Vorasicidenib) | Tablet | Manufacturer recommendation |
| Votrient (PAZOPanib) | Tablet | Manufacturer recommendation; crushing significantly increases AUC and Tmax; hazardous substance _k |
| Vumerity (Diroximel Fumarate) | Capsule | Manufacturer recommendation; delayed release |
| Vykat XR (Diazoxide Choline) | Tablet | Extended release |
| Vyndamax (Tafamidis) | Capsule | Manufacturer recommendation |
| Vyndaqel (Tafamidis) | Capsule | Manufacturer recommendation |
| Wakix (Pitolisant) | Tablet | Canadian manufacturer recommendation (not in US labeling) |
| Wayrilz (Rilzabrutinib) | Tablet | Manufacturer recommendation |
| Welireg (Belzutifan) | Tablet | Manufacturer recommendation |
| Wellbutrin (BuPROPion) | Tablet | Manufacturer recommendation |
| Wellbutrin SR (BuPROPion) | Tablet | Extended release |
| Wellbutrin XL (BuPROPion) | Tablet | Extended release |
| Widaplik (Amlodipine, Indapamide, and Telmisartan) | Tablet | Manufacturer recommendation |
| Xalkori (Crizotinib) | Capsule | Manufacturer recommendation _n ; hazardous substance _k |
| Xalkori (Crizotinib) | Capsule, coated pellets | Oral pellets contained within the capsule; do not crush or chew pellets; manufacturer recommendation; hazardous substance _k |
| Xanax XR (ALPRAZolam) | Tablet | Extended release _b |
| Xartemis XR (Oxycodone and Acetaminophen) | Tablet | Extended release; tablet disruption may cause a potentially fatal overdose |
| Xeljanz XR (Tofacitinib) | Tablet | Extended release; manufacturer recommendation |
| Xeloda (Capecitabine) | Tablet | Manufacturer recommendation _o ; hazardous substance _k |
| Xenleta (Lefamulin) | Tablet | Film-coated; manufacturer recommendation |
| Xigduo XR (Dapagliflozin and Metformin) | Tablet | Extended release |
| Ximino (Minocycline) | Capsule | Extended release |
| Xolremdi (Mavoxifafor) | Capsule | Manufacturer recommendation |
| Xospata (Gilteritinib) | Tablet | Manufacturer recommendation |
| Xpovio (Selinexor) | Tablet | Manufacturer recommendation |
| Xtampza ER (OxyCODONE) | Capsule | Extended release _{a,b} |
| Xtandi (Enzalutamide) | Capsule | Manufacturer recommendation; hazardous substance _k |

| Drug Product | Dosage Form | Reasons/Comments |
|--|-------------------|--|
| Xtandi (Enzalutamide) | Tablet | Manufacturer recommendation; film-coated; hazardous substance _k |
| Yonsa (Abiraterone) | Tablet | Manufacturer recommendation; hazardous substance _k ; caregivers who are or could be pregnant should wear gloves if handling tablets |
| Yosprala (Aspirin and Omeprazole) | Tablet | Delayed release |
| Zegerid OTC (Omeprazole and Sodium Bicarbonate) | Capsule | Delayed release _b |
| Zegfroy (Sunvozertinib) | Tablet | Manufacturer recommendation |
| Zejula (Niraparib) | Capsule | Manufacturer recommendation |
| Zelboraf (Vemurafenib) | Tablet | Manufacturer recommendation (based on tablet properties); hazardous substance _k ; pharmacokinetic amorphous solid dispersion technology may be affected |
| Zenatane (ISOTretinoin) | Capsule | Mucous membrane irritant; teratogenic potential |
| Zenpep (Pancrelipase) | Capsule | Delayed release _a ; enteric-coated contents |
| Zepatier (Elbasvir and Grazoprevir) | Tablet | Pharmacokinetic amorphous solid dispersion technology may be affected |
| Zeposia (Ozanimod) | Capsule | Manufacturer recommendation |
| Zituvimet XR (Sitagliptin and Metformin) | Tablet | Extended release |
| Zokinvy (Lonafarnib) | Capsule | Manufacturer recommendation _a |
| Zolinza (Vorinostat) | Capsule | Manufacturer recommendation _b ; irritant; avoid contact with skin or mucous membranes; use gloves to handle; hazardous substance _k |
| Zolpidem | Capsule | Manufacturer recommendation |
| Zolpidem sublingual | Tablet | Sublingual form _g |
| Zomig-ZMT (ZOLMitraiptan) | Tablet | Orally disintegrating form _g |
| Zonatuss (Benzonatate) | Capsule | Swallow whole; pharmacologic action may cause choking if chewed or opened and swallowed |
| Zortress (Everolimus) | Tablet | Manufacturer recommendation; mucous membrane irritant; hazardous substance _k ; pharmacokinetic amorphous solid dispersion technology may be affected |
| Zubsolv (Buprenorphine and Naloxone) | Sublingual tablet | Sublingual form _g |
| Zunveyl (Benzgalantamine) | Tablet | Delayed release; manufacturer recommendation |
| Zuplenz (Ondansetron) | Film | Sublingual form _g |
| Zyban (BuPROPion) | Tablet | Slow release |
| Zydelig (Idelalisib) | Tablet | Manufacturer recommendation |
| Zyflo CR (Zileuton) | Tablet | Extended release |
| ZyrTEC-D Allergy & Congestion (Cetirizine and Pseudoephedrine) | Tablet | Extended release |
| Zytiga (Abiraterone) | Tablet | Manufacturer recommendation; hazardous substance _k ; caregivers who are or could be pregnant should wear gloves if handling uncoated or broken, damaged, or crushed tablets |

- a. Capsule may be opened and the contents taken without crushing or chewing; soft food, such as applesauce or pudding, may facilitate administration (refer to manufacturer's labeling for specific recommendations); contents may generally be administered via nasogastric tube using an appropriate fluid, provided entire contents are washed down the tube.
- b. Liquid dosage forms of the product are available; however, dose, frequency of administration, and manufacturers may differ from that of the solid dosage form.
- c. Antacids and/or milk may prematurely dissolve the coating of the tablet.
- d. Capsule may be opened and the liquid contents removed for administration.
- e. The taste of this product in a liquid form would likely be unacceptable to the patient; administration via nasogastric tube should be acceptable.
- f. Effervescent tablets must be dissolved in the amount of diluent recommended by the manufacturer.
- g. Tablets/film are made to disintegrate under (or on) the tongue.
- h. Tablet is scored and may be broken in half without affecting release characteristics.
- i. Skin contact may enhance tumor production; avoid direct contact.
- j. Prescribing information recommends that women who are, or may become, pregnant should not handle medication, especially if crushed or broken; avoid direct contact.
- k. Potentially hazardous or hazardous substance; refer to institution-specific guidelines for precautions to observe when handling this substance.
- l. Altering (e.g., chewing, crushing, splitting, opening) the dosage form has not been studied, according to the manufacturer.
- m. The manufacturer's labeling states tablets should not be broken; however, available data do not indicate any safety or efficacy concerns with this practice.
- n. For patients unable to swallow whole, capsules may be opened or tablet may be dispersed in liquid; follow manufacturer instructions for preparation and administration. Use appropriate handling precautions if indicated.
- o. There are published reports of compounded extemporaneous preparation (refer to drug monograph). Use appropriate handling precautions if indicated.
- p. In some cases, dosage form may be opened and/or crushed for enteral feeding tube administration; refer to drug monograph for detailed recommendations.

References

Lexidrug Online, Oral Medications That Should Not Be Crushed or Altered. Waltham, MA: UpToDate, Inc.; September 15, 2025. https://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/4227#monograph-tab-content. Accessed September 19, 2025.